Eli Lilly's Taltz (ixekizumab) has been approved in the US for moderate-to-severe plaque psoriasis, along with Teva's asthma drug Cinqair (reslizumab). The US Food and Drug Administration today ...

Teva Pharmaceuticals’ TEV-479 (olanzapine ... in 2009. It is marketed by Eli Lilly as Zyprexa and a longer-acting version ...

They include a 3% WAC price increase implemented for Eli Lilly’s (NYSE ... such as AbbVie (ABBV), GSK (GSK), and Teva (TEVA), was subject to an FTC warning related to patent violations over ...

On that note, time to hustle. Best of luck, and do keep in touch. … When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously ...

In a report released today, Chris Schott from J.P. Morgan maintained a Hold rating on Teva Pharmaceutical (TEVA – Research Report), with a ...

Argus Research analyst Jasper Hellweg maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) yesterday. The company’s shares ...

The FDA has approved Eli Lilly’s Emgality (galcanezumab ... unapproved therapies such as Botox and anti-seizure medication. Teva’s CGRP drug Ajovy (fremanezumab) was approved by the FDA ...

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.